细胞表面标誌物检测市场－全球产业规模、份额、趋势、机会、预测：按产品、应用、地区和竞争对手划分，2021-2031年

全球细胞表面标誌物检测市场预计将从 2025 年的 104.6 亿美元成长到 2031 年的 159.2 亿美元，复合年增长率为 7.25%。

该领域主要集中于利用专用试剂和分析仪器检测细胞膜上的抗原和蛋白质，以用于诊断和研究目的。推动该行业发展的主要动力是慢性疾病（尤其是癌症）的日益普遍。准确的免疫表型分析对于有效的疾病管理至关重要。此外，向个人化医疗的转变——这种转变高度依赖生物标记分析来制定个人化的治疗策略——也加速了该行业的发展。美国癌症协会估计，到2025年，美国将新增2,041,910例癌症病例，这项数据凸显了可靠的检测技术对于支持早期诊断和治疗计画的迫切需求。

儘管市场前景广阔，但先进设备所需的庞大资本投入仍构成重大障碍。购买流式细胞技术系统和特异性抗体的高昂成本会有效阻碍预算有限地区的普及。此外，解读实验数据的复杂性需要专业人员，这进一步限制了小规模实验室的应用。这些经济和营运方面的障碍可能会减缓检测解决方案的推广，尤其是在新兴医疗基础设施可能缺乏支援先进技术的资源的情况下。

市场驱动因素

精准医疗和标靶治疗的日益普及是推动市场成长的主要动力，也因此对可靠的细胞表面标誌物检测产生了强劲的需求，以支持患者分层和治疗监测。研究人员和临床医生越来越依赖免疫表型分析来识别特定的抗原，例如HER2和PD-1，这些抗原可以作为新型免疫疗法和生物製药的标靶。这种对基于生物标记的干预措施的依赖，推动了对特定抗体和检测试剂盒的需求，而这些抗体和试剂盒对于确定哪些患者适合接受这些先进疗法至关重要。例如，百时美施贵宝公司在2025年2月报告称，其PD-1表面蛋白靶向免疫肿瘤疗法Opdivo在2024年的销售额达到了93亿美元，这体现了这一趋势的商业性影响。这表明精准的标誌物识别与高价值标靶治疗的成功之间存在着至关重要的联繫。

此外，製药公司在生物製剂和细胞疗法领域不断增加的研发投入正在推动产业成长，同时也拓展了药物研发领域的应用范围。对细胞表型进行广泛筛检对于检验新型候选药物至关重要，这也推动了先进检测试剂和流式细胞技术的应用。罗氏控股公司在2025年1月发布的2024年度报告中指出，其核心研发投入达到130.4亿瑞士法郎，凸显了依赖细胞分析的治疗创新领域巨大的资本投入。这种积极的研究也直接惠及诊断技术供应商。例如，赛默飞世尔科技公司在2025年1月发布的报告显示，其全年销售额达428.8亿美元，反映了生命科学服务和工具的巨大需求。

市场挑战

全球细胞表面标誌物检测市场成长的主要障碍之一是购买先进设备所需的高昂资本成本。萤光活化细胞分选和流式细胞技术等技术对于准确鑑定表面蛋白至关重要，但购买这些设备需要大量投资。对于资金有限的研究机构和小规模学术实验室而言，这笔负担尤其沉重。除了初始投资成本外，特异性抗体和系统维护的持续费用也显着增加了整体拥有成本。因此，许多机构被迫限制检测平台的采购或推迟关键设备的更新，这直接阻碍了这些技术的广泛应用。

这些经济限制因素因近期联邦政府削减拨款而加剧，而联邦政府的拨款历来用于支持此类研究所需的基础设施。津贴减少导致各机构无法获得投资资本密集系统所需的流动资金。根据美国医学院协会 (AAMC) 2025 年的数据，美国国立卫生研究院 (NIH) 取消了约 2282 项津贴，总额达 38 亿美元，给教学医院和医学院带来了沉重的财务负担。如此大幅度的削减直接阻碍了市场成长，迫使研究中心降低购买昂贵设备的优先顺序。如果没有稳定的财政支持来抵销这些高昂的资本成本，有效打入预算紧张的市场将会十分困难。

市场趋势

将自动化和人工智慧整合到诊断工作流程中，透过提高细胞标记分析的可重复性和效率，正在从根本上改变市场格局。随着高通量实验室处理日益增长的样本量，人工智慧驱动的设门软体和自动化样本製备系统对于标准化免疫表型分析结果和减少人为误差至关重要。这项技术进步能够快速处理现代疾病监测所需的复杂资料集，并直接影响下一代平台的采购决策。这些能力的策略重要性体现在产业领导者的绩效中。例如，贝克顿·迪金森公司（Becton, Dickinson and Company）公布截至2025年2月的财年季度收入约为52亿美元，并指出其诊断解决方案部门在实验室自动化方面的卓越实力是其成功的关键驱动因素。

同时，用于高参数多重分析的频谱流式细胞技术仪正迅速发展。这主要是由于在详细的分析研究中需要分解重迭的萤光讯号。与传统的基于补偿的技术不同，频谱技术能够分离萤光染料的完整发射光谱，使研究人员能够在单一试管中检测到更多细胞表面标誌物。这项功能在免疫肿瘤学研究中尤其重要，因为该领域需要高解析度来表征稀有细胞亚群。专用仪器的快速成长凸显了市场对这项先进技术的强劲需求。根据Cytek Biosciences公司2025年2月发布的财务报告，该公司仅在2024年就安装了667台新的频谱分析，使其全球安装量达到3034台。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：细胞表面标誌物检测的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 产品类别（流式细胞技术、血液分析仪、细胞影像系统、试剂/试剂盒、其他）
  • 按应用领域（疾病诊断/鑑定、研究/药物发现、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美细胞表面标誌物检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲细胞表面标誌物检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区细胞表面标誌物检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲细胞表面标誌物检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美细胞表面标誌物检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球细胞表面标誌物检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Becton, Dickinson and Company
• Nihon Kohden Corporation
• Sysmex Corporation
• Thermo Fisher Scientific inc.
• Nexcelom Bioscience LLC
• Beckman Coulter Inc.
• Qiagen NV
• IVD Medical Holding Limited
• Agilent Technologies Inc.
• Luminex Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cell Surface Markers Detection Market is projected to expand from a valuation of USD 10.46 Billion in 2025 to USD 15.92 Billion by 2031, reflecting a compound annual growth rate of 7.25%. This sector primarily focuses on using specialized reagents and analytical instruments to detect antigens or proteins located on the cellular plasma membrane for both diagnostic and research purposes. A major force propelling this industry is the rising prevalence of chronic conditions, particularly cancer, which necessitates accurate immunophenotyping for effective disease management. Furthermore, the industry is being accelerated by the transition toward personalized medicine, which relies heavily on biomarker analysis to customize therapeutic strategies. Highlighting this urgency, the American Cancer Society estimates that there will be 2,041,910 new cancer cases in the United States in 2025, a statistic that emphasizes the vital need for dependable detection technologies to aid in early diagnosis and treatment formulation.

Despite these growth prospects, the market encounters substantial obstacles related to the significant capital investment required for advanced instrumentation. The high expense associated with purchasing flow cytometry systems and specific antibodies can effectively block adoption in regions with limited budgets. Moreover, the complexity of interpreting the resulting data necessitates specialized personnel, which further restricts accessibility in smaller laboratory settings. Together, these economic and operational barriers threaten to slow the widespread integration of detection solutions, particularly within emerging healthcare infrastructures that may lack the resources to support such advanced technologies.

Market Driver

The escalating adoption of precision medicine and targeted therapies serves as a primary engine for market expansion, creating a strong demand for reliable cell surface marker detection to support patient stratification and treatment monitoring. Both researchers and clinicians are increasingly dependent on immunophenotyping to pinpoint specific antigens, such as HER2 or PD-1, which act as targets for new immunotherapies and biologic drugs. This reliance on biomarker-guided interventions drives the consumption of specific antibodies and assay kits essential for determining which patients are eligible for these sophisticated treatments. As an example of this trend's commercial impact, Bristol Myers Squibb reported in February 2025 that their immuno-oncology therapy Opdivo, which targets the PD-1 surface protein, achieved $9.3 billion in sales during 2024, illustrating the essential connection between precise marker identification and the success of high-value targeted regimens.

Additionally, the industry is being propelled by expanding applications within pharmaceutical research and development, as companies increase their investment in creating biologics and cell-based therapies. Validating new drug candidates necessitates the extensive screening of cellular phenotypes, which in turn drives the acquisition of advanced detection reagents and flow cytometry instruments. In its 2024 Annual Report released in January 2025, Roche Holding AG noted that its core research and development investments hit CHF 13.04 billion, highlighting the immense capital commitment toward therapeutic innovations that depend on cellular analysis. This robust research activity directly advantages diagnostic technology providers; for instance, Thermo Fisher Scientific Inc. reported full-year revenue of $42.88 billion in January 2025, reflecting the massive scale of demand for life sciences services and tools.

Market Challenge

A significant impediment to the growth of the Global Cell Surface Markers Detection Market is the high capital cost required for advanced instrumentation. While technologies like fluorescence-activated cell sorting and flow cytometry are critical for the accurate identification of surface proteins, procuring this machinery demands a heavy financial commitment. This burden is especially restrictive for research facilities and smaller academic laboratories that operate with limited funding. When the initial acquisition price is combined with ongoing expenses for specific antibodies and system maintenance, the total cost of ownership becomes a major deterrent. As a result, many institutions are compelled to limit their purchase of detection platforms or postpone essential equipment upgrades, which directly stifles the broader uptake of these technologies.

These economic constraints are further intensified by recent reductions in federal funding, which has traditionally supported the infrastructure necessary for this type of research. A decrease in grant availability restricts the liquidity institutions require to invest in capital-intensive systems. According to data from the Association of American Medical Colleges in 2025, the cancellation of approximately 2,282 National Institutes of Health grants, amounting to $3.8 billion, has placed significant financial strain on teaching hospitals and medical schools. Such drastic cuts directly impede market growth, as research centers are forced to deprioritize the purchase of expensive instruments. Without consistent financial backing to offset these high capital costs, the market faces difficulties in effectively penetrating sectors that are constrained by tight budgets.

Market Trends

The incorporation of automation and artificial intelligence into diagnostic workflows is fundamentally transforming the market by improving the reproducibility and efficiency of cell marker analysis. As laboratories dealing with high throughputs encounter growing sample volumes, AI-driven gating software and automated sample preparation systems are becoming indispensable for standardizing immunophenotyping results and mitigating manual errors. This technological evolution enables the rapid processing of the complex datasets necessary for modern disease monitoring, thereby directly shaping purchasing decisions regarding next-generation platforms. The strategic importance of these capabilities is reflected in the performance of key industry leaders; for example, Becton, Dickinson and Company reported quarterly revenue of roughly $5.2 billion in February 2025, citing specific strength in Lab Automation within its Diagnostic Solutions segment as a primary factor in this operational success.

Concurrently, the shift toward spectral flow cytometry for high-parameter multiplexing is gaining considerable momentum, fueled by the necessity to resolve overlapping fluorescence signals in deep profiling studies. In contrast to traditional compensation-based techniques, spectral technology unmixes the complete emission signature of fluorochromes, allowing researchers to detect a greater number of cell surface markers within a single tube. This capability is especially vital for immuno-oncology research, where the characterization of rare cell subsets requires granular resolution. The market's strong demand for this advanced technology is evidenced by the rapid growth of specialized instrument bases; according to Cytek Biosciences' financial results released in February 2025, the company expanded its global footprint to 3,034 instruments, having installed 667 new spectral analysis units in 2024 alone.

Key Market Players

• Becton, Dickinson and Company
• Nihon Kohden Corporation
• Sysmex Corporation
• Thermo Fisher Scientific inc.
• Nexcelom Bioscience LLC
• Beckman Coulter Inc.
• Qiagen NV
• IVD Medical Holding Limited
• Agilent Technologies Inc.
• Luminex Corporation

Report Scope

In this report, the Global Cell Surface Markers Detection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Surface Markers Detection Market, By Product

• Flow Cytometry
• Hematology Analyzers
• Cell Imaging Systems
• Reagents and Kits
• Other

Cell Surface Markers Detection Market, By Application

• Disease Diagnosis And Identifications
• Research And Drug Discovery
• Others

Cell Surface Markers Detection Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Surface Markers Detection Market.

Available Customizations:

Global Cell Surface Markers Detection Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Surface Markers Detection Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Flow Cytometry, Hematology Analyzers, Cell Imaging Systems, Reagents and Kits, Other)
  • 5.2.2. By Application (Disease Diagnosis And Identifications, Research And Drug Discovery, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Cell Surface Markers Detection Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Surface Markers Detection Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Cell Surface Markers Detection Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Cell Surface Markers Detection Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Cell Surface Markers Detection Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Surface Markers Detection Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. France Cell Surface Markers Detection Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Cell Surface Markers Detection Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Cell Surface Markers Detection Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Cell Surface Markers Detection Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia Pacific Cell Surface Markers Detection Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Surface Markers Detection Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Cell Surface Markers Detection Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Cell Surface Markers Detection Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Cell Surface Markers Detection Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Cell Surface Markers Detection Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. Middle East & Africa Cell Surface Markers Detection Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Surface Markers Detection Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Cell Surface Markers Detection Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Cell Surface Markers Detection Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. South America Cell Surface Markers Detection Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Surface Markers Detection Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Cell Surface Markers Detection Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Cell Surface Markers Detection Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Surface Markers Detection Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Becton, Dickinson and Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Nihon Kohden Corporation
• 15.3. Sysmex Corporation
• 15.4. Thermo Fisher Scientific inc.
• 15.5. Nexcelom Bioscience LLC
• 15.6. Beckman Coulter Inc.
• 15.7. Qiagen NV
• 15.8. IVD Medical Holding Limited
• 15.9. Agilent Technologies Inc.
• 15.10. Luminex Corporation

16. Strategic Recommendations

17. About Us & Disclaimer